Full text
PDFPage 1293
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Guslandi M. Importance of defensive factors in the prevention of peptic ulcer recurrence. Role of carbenoxolone sodium. Acta Gastroenterol Belg. 1983 Sep-Oct;46(9-10):411–418. [PubMed] [Google Scholar]
- Lam S. K. Implications of sucralfate-induced ulcer healing and relapse. Am J Med. 1989 Jun 9;86(6A):122–126. doi: 10.1016/0002-9343(89)90172-1. [DOI] [PubMed] [Google Scholar]
- McLean A. J., Harrison P. M., Ioannides-Demos L., Byrne A. J., McCarthy P., Dudley F. J. The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term clinical outcome. Aust N Z J Med. 1985 Jun;15(3):367–374. doi: 10.1111/j.1445-5994.1985.tb04065.x. [DOI] [PubMed] [Google Scholar]
- Miller J. P., Faragher E. B. Relapse of duodenal ulcer: does it matter which drug is used in initial treatment? Br Med J (Clin Res Ed) 1986 Nov 1;293(6555):1117–1118. doi: 10.1136/bmj.293.6555.1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miller J. P., Faragher E. B. The potential impact of Campylobacter pylori on the treatment of duodenal ulcer disease. Scand J Gastroenterol Suppl. 1989;160:39–45. doi: 10.3109/00365528909091734. [DOI] [PubMed] [Google Scholar]
- Rauws E. A., Tytgat G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990 May 26;335(8700):1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]